- Previous Close
7.66 - Open
7.50 - Bid 7.35 x 5700
- Ask 7.44 x 1600
- Day's Range
7.05 - 7.73 - 52 Week Range
5.60 - 15.74 - Volume
13,945,342 - Avg. Volume
9,910,995 - Market Cap (intraday)
2.887B - Beta (5Y Monthly) 0.80
- PE Ratio (TTM)
-- - EPS (TTM)
-1.54 - Earnings Date Feb 25, 2025 - Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.86
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
www.recursion.comRecent News: RXRX
View MorePerformance Overview: RXRX
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RXRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RXRX
View MoreValuation Measures
Market Cap
2.89B
Enterprise Value
2.55B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
28.10
Price/Book (mrq)
5.50
Enterprise Value/Revenue
39.48
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.40%
Return on Equity (ttm)
-78.49%
Revenue (ttm)
65.18M
Net Income Avi to Common (ttm)
-377.75M
Diluted EPS (ttm)
-1.54
Balance Sheet and Cash Flow
Total Cash (mrq)
427.65M
Total Debt/Equity (mrq)
17.28%
Levered Free Cash Flow (ttm)
-186.33M